Nymox Pharmaceutical Corporation

About Nymox Pharmaceutical Corporation

Nymox Pharmaceutical Corporation is dedicated to introducing a new, safe, efficacious, and long-lasting therapy for millions of men suffering from an enlarged prostate gland, known as Benign Prostate Hyperplasia (BPH).

Products & Services

Fexapotide Triflutate:A novel injectable therapy for the treatment of Benign Prostate Hyperplasia (BPH).

NicAlert(r):A product offered by Nymox, specific details not provided in the content.

Specialties

Benign Prostate Hyperplasia (BPH) treatment Injectable therapy for prostate gland cells Research in low-grade localized prostate cancer

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Private Placement T: - FT: Private Placement	A: 2000000 MR: - FA: 2 million FAN: 2000000	D: 2023-08-29 FD: 2023-08-29	1 investors
2	RT: Private Placement T: - FT: Private Placement	A: 2000000 MR: - FA: 2.0 million FAN: 2000000	D: 2023-08-02 FD: 2023-08-02	1 investors

Private Placement Latest

2023-08-29

$2.0M

1 investor (Pro only)

Private Placement 2023-08-02

$2.0M

View 1 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

P

Paul Averback

President and CEO

S

Suresh Kalbag

Director of CMC Operations

J

James G. Robinson

Director

D

David Morse

Professor and Director

View 1 more team members with Pro

Unlock Full Team Directory

Recent News